Download Velindre Cancer Centre

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts

Infection control wikipedia, lookup

Cancer immunotherapy wikipedia, lookup

Hospital-acquired infection wikipedia, lookup

Transcript
11th May 2010
Velindre Cancer Centre
Presenter: Professor Peter Barrett-Lee, Medical Director
Content Area
Drivers
Measurement
Interventions
Tests of change
To continue with
Oncology Trigger Tool
audits
To develop a trigger tool for
oncology ambulatory/day care
treatment settings
To reduce
harm by 5%
Improve
General Care
within
inpatient
areas
Medicines
Management
Spread OGTT to other
Oncology Centres
Undertake case note
review of 50 patients to
establish triggers
To reduce incidence of
pressure sores and falls
Implement skin bundle and risk
assessments
Spread Releasing time to care
to remaining inpatient wards
Spread regular review
processes to all wards
VCC custom measures:
To ensure that regular opioid analgesia
is being administered as prescribed
To ensure the effectiveness of
breakthrough pain relief
To determine an early indicator of
opiate toxicity in patients
To improve the incidence and
risk of thrombosis in cancer
patients
Improve compliance with
antimicrobial policy
Infection
Control
Reduce incidence of
UTI’s
Continue with audit and
analyse results.
Develop action plan including
education.
Present at CPT meeting
Establish thrombosis group and
partake in collaborative.
Introduce LMWH to all
appropriate inpatients
Audit of antibiotic usage
Implement care bundle
for UTI’s
Content Area
Drivers
Measurement
Interventions
Tests of change
To investigate the use of
HSMR in an oncology
treatment setting
Arrange workshop with relevant parties to explore
further.
Review VCC coding practice for palliative care
To analyse cancer survival
outcomes by tumour or
sub-tumour site
All Clinical Process Teams to
agree one survival measure for
tumour group
To implement systems for
mortality case note
reviews
To reduce
mortality
Chemotherapy /
Cytotoxic Drugs
RRAILS
To audit patient deaths
within 30 days of
commencing chemo
Spread Sepsis 6 and care
bundle approach to all
ward areas
Develop and implement action
plan sharing results with other
centres to promote learning
across boundaries
Spread education sessions and
lessons through Critical Care
Lead
Breast Cancer (97 – 09) Female cases,
New diagnosisBreast
(ALL),
Radical intent
cancer (97-09),
Female cases, New diagnoses (ALL), Radical intent
Overall SurvivalOverall Survival
Comparison with UK
and Europe
• Eurocare-4 (Lancet Oncol 2007; 8: 784-96) suggested that there are
still breast cancer survival differences between the UK and mainland
Europe – European average 5-year age-adjusted breast cancer
survival of 79% for the 2000-02 period analysis
• England was given at 77.8% compared to individual figures for
Finland (85.7%) and Norway (84.1%) at 5 years.
• Cambridge and East Anglia 7-year OS was 87% (C) and 84% (EA).
• Velindre Cancer Centre OS at 5 years 83.1% (97-09 data)
Aim: To Improve overall survival for all Cancer
Sites